

**CORRIGENDUM TO THE NOTICE OF THE 01/2026-27 EXTRA ORDINARY GENERAL MEETING (“EGM”)**

This Corrigendum is being issued in continuation of the 01/2026-27 Extra Ordinary General Meeting (EGM) notice dated 06th May 2026 (“Notice”) for the EGM of the shareholders of Anondita Medicare Limited (“Company”) which is scheduled to be held on **Thursday 28th May 2026 at 01:00 P.M.** at the registered office of the company situated at Flat No.704 Narmada Blk,N6, Sec-D, Pkt-6 Vasant Kunj, New Delhi – 110070 through Video Conferencing (“VC”)/ Other Audio-Visual Means (“OAVM”). The notice of 01/2026-27 EGM was dispatched to the shareholders of the Company on 06th May 2026 electronically in due compliance with the provisions of the Companies Act, 2013, as amended, and the rules made thereunder (the “Companies Act”), read with circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India (“SEBI”), to transact the business stated therein.

This corrigendum to the EGM Notice (“Corrigendum”) is issued to provide certain clarifications pursuant to the suggestions / comments received from National Stock Exchange of India Limited vide their letter Ref: NSE/LIST/55045 dated May 11, 2026 with respect to the following points:

- A) Change in the relevant date from 27 April 2026 to 28 April 2026 in order to comply with the requirements of Regulation 161 of the SEBI (ICDR) Regulations;
- B) Revision in Valuation, due to change in Relevant Date;
- C) Change in Issue Price and Consideration Amount;
- D) A detailed explanation of the “certification costs” as mentioned in the object of the issue.

All other contents of the Notice remain the same.

This corrigendum to the Notice shall form an integral part of the Notice which has already been circulated to the shareholders of the Company. Accordingly, the Notice shall always be read in conjunction with this corrigendum. This corrigendum is available on the website of the Company at <https://anonditamedicare.com/inc/Corrigendum.pdf> and on the website of the National Stock Exchange at www.nseindia.com.

A) CHANGE IN RELEVANT DATE

a) In the Notice under “Item No. 1”, Para Number 2 should be read as follows:

RESOLVED FURTHER THAT in terms of the provisions of Chapter V of the SEBI ICDR Regulations, the “**Relevant Date**” for the purpose of determination of the floor price for the issue and allotment of Warrants is Tuesday, April 28, 2026, being the date 30 (thirty) days prior to the date of this Extra Ordinary General Meeting.





- b) In the explanatory statement to the Notice for “Item No. 1”, Point No 5 should be read as follows:

The “**Relevant Date**” as per Chapter V of the SEBI ICDR Regulations, for the determination of the floor price for Warrants to be issued is Tuesday, April 28, 2026 i.e. 30 (thirty) days prior to the date of this Extra Ordinary General Meeting which is May 28, 2026 to approve the proposed preferential issue.

- c) In the explanatory statement to the Notice for “Item No. 1”, Point No 23 should be read as follows:

23. Practicing Company Secretary’s Certificate

The Certificate from Mr. Mohit Singhal, Practicing Company Secretary (FCS 11143 | CP 15995), Proprietor of Mohit Singhal & Associates, Company Secretaries, certifying that the Preferential Issue is being made in accordance with the requirements contained in the SEBI ICDR Regulations shall be made available for inspection by the Members during the meeting and will be accessible at link: <https://anonditamedicare.com/inc/Revised%20PCS%20Certificate.pdf>

B) REVISION IN VALUATION, DUE TO CHANGE IN RELEVANT DATE

- a) In the explanatory statement to the Notice for “Item No. 1”, Point No 6 should be read as follows:

6. Basis on which the Price has been arrived at along with report of the Registered Valuer

The Board of the Company has fixed the Issue price of ₹1038/- (Rupees One Thousand and Thirty-Eight Only) each, which is above the Minimum Price as determined in compliance with the requirements of the SEBI ICDR Regulations.

The Minimum price of ₹1038/- (Rupees One Thousand and Thirty-Eight Only) per Warrant in accordance with Regulation 164 of SEBI (ICDR) Regulations was performed by Mr. Ankush Garg, a Registered Valuer (Registration No. IBBI/RV/02/2018/10010) having his office located at A - 3 / 85, Sector 3, Rohini, Delhi - 110085.

The shares of the Company are listed on NSE Emerge Platform and are frequently traded. Further, the Articles of Association of the Company does not provide for any particular method of determination of price. Therefore, the price is determined in compliance with Regulation 164 of SEBI ICDR Regulations for Preferential Issues taking into account valuation parameters including book value, comparable trading multiples and such other parameters as are customary for valuation of shares.





The valuation was performed by Mr. Ankush Garg, a Registered Valuer (Registration No. IBBI/RV/02/2018/10010) having his office located at A - 3 / 85, Sector 3, Rohini, Delhi – 110085 in accordance with regulation 164 of SEBI (ICDR) Regulations. The revised certificate of Independent Valuer confirming the minimum price for preferential issue as per chapter V of SEBI (ICDR) Regulations is available for inspection at the Registered Office of the Company between 10:00 A.M. to 05:00 P.M. on all working days upto the date of EGM and uploaded on the website of the Company. The link of Valuation Report is <https://anonditamedicare.com/inc/Revised%20Valuation%20Report.pdf>

C) CHANGE IN ISSUE PRICE AND CONSIDERATION AMOUNT

a) *In the Notice under “Item No. 1”, Para 1 of Resolution should be read as follows:*

“RESOLVED THAT pursuant to the provisions of Sections 42, 62(1)(c) and other applicable provisions, if any, of the Companies Act, 2013, as amended (the “**Act**”), the Companies (Prospectus and Allotment of Securities) Rules, 2014, the Companies (Share Capital and Debentures) Rules, 2014 and other applicable rules made thereunder (including any statutory modification(s) or re-enactment(s) thereof), for the time being in force, and in accordance with the Foreign Exchange Management Act, 1999, as amended or restated (“**FEMA**”), and rules, circulars, notifications, regulations and guidelines issued under FEMA, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (the “**SEBI ICDR Regulations**”) and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “**SEBI Listing Regulations**”), as amended from time to time, and subject to any other rules, regulations, guidelines, notifications, circulars and clarifications issued thereunder from time to time by the Ministry of Corporate Affairs, the Reserve Bank of India, the Securities and Exchange Board of India and/or any other statutory or regulatory authorities, including the National stock Exchange of India Limited (the “**NSE**”), on which the equity shares of the Company having face value of ₹ 10/- (Indian Rupees Ten) each (“**Equity Shares**”) are listed (hereinafter collectively referred to as “**Applicable Regulatory Authorities**”) from time to time to the extent applicable, and the enabling provisions of the Memorandum of Association and Articles of Association of the Company, and subject to such approval(s), consent(s) and permission(s) as may be necessary or required, from Applicable Regulatory Authorities (including the NSE) and subject to such conditions and modifications as may be imposed or prescribed while granting such approvals, consents and permissions, which the Board of Directors of the Company (hereinafter referred to as the “**Board**”, which term shall be deemed to mean and include one or more committee(s) constituted by the Board to exercise its powers including the powers conferred by this resolution), the consent of the Members of the Company be and is hereby accorded to the Board to create, issue, offer and allot, from time to time, in one or more tranches, up to 2,85,000 (Two Lakh and Eighty Five Thousand Only) Convertible Warrants, each convertible into, or exchangeable for, onefully paid-up Equity Shares of the Company of face Value ₹ 10.00/- (Rupees Ten only) (“**Convertible Warrant**”) at a price of ₹ 1,038/- (Rupees One Thousand and Thirty-Eight Only) (including a premium of ₹ 1,028/- (Rupees One Thousand and Twenty-Eight Only) each payable in cash (“**Warrant Issue Price**”)





ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSO CERTIFIED CO.
Manufacturer of Condoms

aggregating up to ₹ 29,58,30,000 /- (Rupees Twenty Nine Crore Fifty-Eight Lakhs and Thirty Thousand Only) to persons who belongs to Promoter Category which may be exercised in one or more tranches during the period commencing from the date of allotment of the Warrants until expiry of 18 (Eighteen) months, to the following persons/entities(hereinafter referred to as “**Proposed Allottees**”), by way of a preferential issue in accordance with the terms of the Warrants as set out herein, and in the explanatory statement to this Notice calling EGM, and on such other terms and conditions as set out herein, subject to applicable laws and regulations, including the provisions of Chapter V of the SEBI ICDR Regulations and the Act, as the Board may determine (the “**Preferential Issue**”):

S.No.	Name of Investor	Category	No. of Warrant Proposed to be issued	Amount
1.	Mr. Anupam Ghosh	Promoter	2,85,000	29,58,30,000

b) In the Notice under “Item No. 1”, Para 3(b) of Resolution should be read as follows:

The minimum amount of ₹7,39,57,500/- (Rupees Seven Crores Thirty-Nine Lakhs Fifty-Seven Thousand and Five Hundred Only) which is equivalent to 25 % (twenty five percent) of the Warrants Issue Price in aggregate shall be paid at the time of subscription and allotment of each Warrant. The Warrant holders will be required to make further payments of ₹22,18,72,500/- (Rupees Twenty-Two Crores Eighteen Lakhs Seventy-Two Thousand and Five Hundred Only) which is equivalent to 75% (seventy five percent) of the Warrants Issue size in aggregate at the time of exercise of the right attached to the Warrant(s), to convert the Warrant(s) into equity share(s) of the Company (“**Warrant Exercise Amount**”).

c) In the explanatory statement to the Notice for “Item No. 1”, Para 1 and 2 of the preamble should be read as follows:

The Board of Directors of the Company (“Board”) at their meeting held on April 30, 2026, has approved raising of funds aggregating up to ₹ 29,58,30,000 /- (Rupees Twenty Nine Crore Fifty-Eight Lakhs and Thirty Thousand Only), by way of issuance of up to 2,85,000 (Two Lakhs and Eighty Five Thousand Only) warrants, each convertible into, or exchangeable for, one fully paid-up Equity Shares of the Company of face Value ₹ 10.00/- (Rupees Ten Only) (“Convertible Warrant”) to certain identified promoter persons as mentioned below (“Warrant Holders”/ “Proposed Allottees”) at a price of ₹ 1038/- (Rupees One Thousand and Thirty-Eight Only) each payable in cash (including the warrant subscription price and the warrant exercise price), aggregating up to ₹ 29,58,30,000 /- (Rupees Twenty Nine Crore Fifty-Eight Lakhs and Thirty Thousand Only), which may be exercised in one or more tranches during the period commencing from the date of allotment of the Warrants until expiry of 18 (Eighteen) months, to the following people (referred to as the “Proposed Allottees”), by way of a preferential issue through private placement offer (the “Preferential Issue”):





S. No.	Name of the Proposed Allottee(s)	Convertible Warrants to be allotted	Consideration (in ₹)
1.	Anupam Ghosh	2,85,000	29,58,30,000
	Total	2,85,000	29,58,30,000

In this regard, the Board, pursuant to its resolution dated April 30, 2026, has noted and accepted the investment commitment letters issued by the Proposed Allottees to the Company for investment of aggregate amount up to an amount of ₹ 29,58,30,000/- (Rupees Twenty Nine Crore Fifty-Eight Lakhs and Thirty Thousand Only), in the Company, subject to customary closing conditions.

d) In the explanatory statement to the Notice for "Item No. 1", Point No 1, 2, 7, 10 and 19 should be read as follows:

1. Particulars of the Preferential Issue including date of passing of Board Resolution

The Board, at its meeting held on April 30, 2026 has, subject to the approval of the Members and such other approvals as may be required, approved the issuance of up to 2,85,000 (Two Lakhs and Eighty Five Thousand Only) warrants, each convertible into, or exchangeable for, one fully paid-up Equity Shares of the Company of face Value ₹ 10.00/- (Rupees Ten Only) ("Warrant") at a price ₹ 1,038/- (Rupees One Thousand and Thirty-Eight Only) (including a premium of ₹ 1,028/-) (Rupees One Thousand and Twenty-Eight Only) each payable in cash ("Warrant Issue Price") aggregating up to ₹ 29,58,30,000/- (Rupees Twenty Nine Crore Fifty-Eight Lakhs and Thirty Thousand Only) for a cash consideration, by way of a preferential issue on a private placement basis.

The proposed preferential issue shall not result in any change in control or management of the Company.

2. Kinds of securities offered and the price at which security is being offered, and the total/ maximum number of securities to be issued.

The Company proposes to offer, issue and allot, in one or more tranches upto 2,85,000 (Two Lakhs and Eighty Five Thousand) warrants, each convertible into, or exchangeable for, one fully paid-up Equity Shares of the Company of face Value ₹ 10.00/- (Rupees Ten Only) ("Warrant") at a price of ₹ 1,038/- (Rupees One Thousand and Thirty-Eight Only) (including a premium of ₹ 1,028/-) (Rupees One Thousand and Twenty-Eight Only) each payable in cash ("Warrant Issue Price") aggregating up to ₹ 29,58,30,000/- (Rupees Twenty Nine Crore





ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSO CERTIFIED CO.
Manufacturer of Condoms

Fifty-Eight Lakhs and Thirty Thousand Only) (“**Total Issue Size**”) by way of a Preferential Issue.

7. Amount which the Company intends to raise by way of such convertible warrants.

Aggregating up to ₹ 29,58,30,000 /- (Rupees Twenty Nine-Crore Fifty-Eight Lakhs and Thirty Thousand Only), out of which ₹ 7,39,57,500/- (Rupees Seven Crores Thirty-Nine Lakhs Fifty-Seven Thousand and Five Hundred Only), which is 25% of the warrants issue, will be raised at the time of allotment and balance ₹22,18,72,500/- (Rupees Twenty-Two Crores Eighteen Lakhs Seventy-Two Thousand and Five Hundred Only) which is equivalent to 75% (seventy five percent) of the Warrants Issue Size in aggregate at the time of exercise of the right attached to the Warrant(s), to convert the Warrant(s) into equity share(s) of the Company.

10. Maximum number of securities to be issued

The Company proposes to offer, issue and allot, up to 2,85,000 (Two Lakhs and Eighty Five Thousand Only) warrants, each convertible into, or exchangeable for, one fully paid-up Equity Shares of the Company of face Value ₹ 10.00/- (Rupees Ten Only) (“**Convertible Warrant**”) at a price of ₹ 1,038/- (Rupees One Thousand and Thirty-Eight Only) (including a premium of ₹ 1,028/-) (Rupees One Thousand and Twenty-Eight Only) each payable in cash (“**Warrant Issue Price**”) aggregating up to ₹ 29,58,30,000 /- (Rupees Twenty Nine Crore Fifty-Eight Lakhs and Thirty Thousand Only), by way of a Preferential Issue.

Minimum amount of ₹259.5/- (Rupees Two Hundred and Fifty-Nine and Fifty Paise Only) per Warrant, which is equivalent to 25% (twenty-five percent) of the Warrants Issue Price shall be paid at the time of subscription and allotment of each Warrant. The warrant holder will be required to make further payments of ₹778.5/- (Rupees Seven Hundred and Seventy-Eight and Fifty Paise Only) for each Warrant, which is equivalent to 75% (seventy-five percent) of the Warrants Issue Price at the time of exercise of the right attached to Warrant(s) to subscribe to equity share(s).

The price for the allotment of shares to be issued is based on the minimum price determined in accordance with Chapter V of SEBI ICDR Regulations is fixed at ₹ 1038/- (Rupees One Thousand and Thirty-Eight Only) per Convertible Warrant.

19. Contribution being made by the promoters or directors either as part of the Preferential Issue or separately in furtherance of objects.

Upto ₹ 29,58,30,000 /-



**D) A DETAILED EXPLANATION OF THE “CERTIFICATION COSTS” AS MENTIONED IN THE OBJECT OF THE ISSUE.**

a) In the explanatory statement to the Notice for “Item No. 1”, Point No 3 should be added an explanation to the certification cost as follows:

The certification costs relate to obtaining necessary regulatory approvals, certifications, registrations, and prequalifications required for manufacturing and export of condoms in domestic as well as international markets. The Company primarily proposes to obtain World Health Organization/United Nations Population Fund (WHO/UNFPA) Prequalification for male condoms and Conformité Européenne (CE) Certification under the European Medical Device Regulations (MDR), along with export registrations in various jurisdictions and other applicable regulatory approvals, including United States Food and Drug Administration (USFDA) approvals and other country-specific certifications, as may be required from time to time.

The WHO/UNFPA Prequalification process involves expenditure towards assessment fees, annual retention fees, change assessment fees, technical documentation assessment, and re-inspection charges, wherever applicable. The CE Certification process involves expenditure towards ISO 13485 certification, preparation and maintenance of technical documentation, product testing, Notified Body audits and annual surveillance requirements.

In addition, the certification process generally involves expenditure towards product testing (including burst, leakage, shelf life, and biocompatibility testing), factory inspections, audit preparation, stability studies, preparation of clinical and technical dossiers, and consultancy and documentation charges required for compliance with applicable regulatory standards.

All other contents of the EGM Notice, save and except as modified or supplemented by the Corrigendum, shall remain unchanged.

**By Order of the Board of Directors of
Anondita Medicare Limited**

**Sd/-
Bhawna Bisht
Company Secretary & Compliance Officer
Membership No.:A70843**

Date: 18/05/2026
Place: Uttar Pradesh

